SRNE - Sorrento Therapeutics Stock Price, News & Analysis

$2.25 -0.10 (-4.26 %)
(As of 11/24/2017 04:03 AM ET)
Previous Close$2.35
Today's Range$2.20 - $2.35
52-Week Range$1.50 - $6.10
Volume484,000 shs
Average Volume827,942 shs
Market Capitalization$186.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.7

About Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics logoSorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRNE
CUSIPN/A

Debt

Debt-to-Equity Ratio0.18%
Current Ratio0.54%
Quick Ratio0.54%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.15 million
Price / Sales21.90
Cash FlowN/A
Price / CashN/A
Book Value$1.74 per share
Price / Book1.29

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($0.73)
Net Income$-60,920,000.00
Net Margins-15.62%
Return on Equity-26.98%
Return on Assets-6.39%

Miscellaneous

Employees154
Outstanding Shares79,320,000

Frequently Asked Questions for Sorrento Therapeutics (NASDAQ:SRNE)

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) announced its earnings results on Monday, November, 16th. The biopharmaceutical company reported ($0.03) EPS for the quarter. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.28 million. Sorrento Therapeutics had a negative return on equity of 26.98% and a negative net margin of 15.62%. View Sorrento Therapeutics' Earnings History.

Where is Sorrento Therapeutics' stock going? Where will Sorrento Therapeutics' stock price be in 2017?

5 analysts have issued twelve-month target prices for Sorrento Therapeutics' stock. Their forecasts range from $6.00 to $20.00. On average, they expect Sorrento Therapeutics' stock price to reach $12.40 in the next year. View Analyst Ratings for Sorrento Therapeutics.

Who are some of Sorrento Therapeutics' key competitors?

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the folowing people:

  • William S. Marth, Independent Chairman of the Board (Age 61)
  • Henry H. Ji Ph.D., President, Chief Executive Officer, Director (Age 63)
  • Kevin Herde, Chief Financial Officer, Executive Vice President
  • Mike Royal M.D., Executive Vice President - Clinical and Regulatory Affairs (Age 61)
  • Miranda Jayne Toledano, Executive Vice President - Corporate Development
  • George Uy, Executive Vice President, Chief Commercial Officer (Age 59)
  • David Miao, Chief Technology Officer (Age 51)
  • Jaisim Shah, Director (Age 54)
  • Yue Wu Ph.D., Director
  • David H. Deming, Independent Director (Age 62)

Who owns Sorrento Therapeutics stock?

Sorrento Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (0.10%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde, Patrick Soon-Shiong and Yue Alexander Wu. View Institutional Ownership Trends for Sorrento Therapeutics.

Who bought Sorrento Therapeutics stock? Who is buying Sorrento Therapeutics stock?

Sorrento Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu. View Insider Buying and Selling for Sorrento Therapeutics.

How do I buy Sorrento Therapeutics stock?

Shares of Sorrento Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of Sorrento Therapeutics stock can currently be purchased for approximately $2.25.

How big of a company is Sorrento Therapeutics?

Sorrento Therapeutics has a market capitalization of $186.41 million and generates $8.15 million in revenue each year. The biopharmaceutical company earns $-60,920,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Sorrento Therapeutics employs 154 workers across the globe.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]


MarketBeat Community Rating for Sorrento Therapeutics (SRNE)

Community Ranking:  4.1 out of 5 (star star star star)
Outperform Votes:  215 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Sorrento Therapeutics (NASDAQ:SRNE)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.40 (451.11% upside)

Consensus Price Target History for Sorrento Therapeutics (NASDAQ:SRNE)

Price Target History for Sorrento Therapeutics (NASDAQ:SRNE)

Analysts' Ratings History for Sorrento Therapeutics (NASDAQ:SRNE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$7.00 -> $6.00N/AView Rating Details
10/5/2017HC WainwrightReiterated RatingBuy$20.00N/AView Rating Details
8/3/2017Roth CapitalInitiated CoverageBuy$7.00HighView Rating Details
6/17/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/22/2017Rodman & RenshawLower Price TargetBuy -> Buy$30.00 -> $20.00HighView Rating Details
8/12/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Sorrento Therapeutics (NASDAQ:SRNE)

Earnings by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Earnings History by Quarter for Sorrento Therapeutics (NASDAQ SRNE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/16/2015Q315($0.03)$1.28 million$1.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.32)($0.27)$0.08 million$1.28 millionViewN/AView Earnings Details
8/6/2014($0.34)($0.33)$0.08 million$0.78 millionViewN/AView Earnings Details
5/14/2014($0.29)($0.44)$0.12 million$0.98 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sorrento Therapeutics (NASDAQ:SRNE)
2017 EPS Consensus Estimate: ($1.25)
2018 EPS Consensus Estimate: ($1.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20171($0.34)($0.34)($0.34)
Q3 20172($0.35)($0.21)($0.28)
Q4 20172($0.38)($0.21)($0.30)
Q1 20181($0.29)($0.29)($0.29)
Q2 20181($0.28)($0.28)($0.28)
Q3 20181($0.26)($0.26)($0.26)
Q4 20181($0.24)($0.24)($0.24)
Q1 20191($0.22)($0.22)($0.22)
Q2 20191($0.19)($0.19)($0.19)
Q3 20191($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sorrento Therapeutics (NASDAQ:SRNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sorrento Therapeutics (NASDAQ SRNE)

Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 15.33%
Insider Trades by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Institutional Ownership by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Insider Trades by Quarter for Sorrento Therapeutics (NASDAQ SRNE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/15/2017Henry JiInsiderBuy29,001$1.81$52,491.81View SEC Filing  
6/15/2017Jaisim ShahDirectorBuy10,002$1.79$17,903.58View SEC Filing  
4/19/2017Abg Management LtdMajor ShareholderBuy550,000$2.00$1,100,000.00View SEC Filing  
4/19/2017Henry JiCEOBuy100,000$2.00$200,000.00View SEC Filing  
4/13/2017Abg Management LtdMajor ShareholderBuy2,500,000$2.00$5,000,000.00View SEC Filing  
2/22/2017Henry JiInsiderBuy2,000$5.60$11,200.00View SEC Filing  
2/10/2017Henry JiInsiderBuy20,000$5.15$103,000.00View SEC Filing  
2/3/2017Jerome B ZeldisInsiderBuy10,000$5.15$51,500.00View SEC Filing  
2/3/2017Kevin HerdeVPBuy3,000$5.15$15,450.00View SEC Filing  
2/3/2017Yue Alexander WuDirectorBuy5,000$5.15$25,750.00View SEC Filing  
6/29/2016Patrick Soon-ShiongMajor ShareholderSell3,400$5.82$19,788.00View SEC Filing  
6/23/2016Patrick Soon-ShiongMajor ShareholderSell6,901$5.85$40,370.85View SEC Filing  
6/15/2016Patrick Soon-ShiongMajor ShareholderSell19,836$5.87$116,437.32View SEC Filing  
6/14/2016Patrick Soon-ShiongMajor ShareholderSell53,764$6.14$330,110.96View SEC Filing  
6/13/2016Patrick Soon-ShiongMajor ShareholderSell37,792$6.15$232,420.80View SEC Filing  
3/7/2016Patrick Soon-ShiongMajor ShareholderSell100,000$6.19$619,000.00View SEC Filing  
8/26/2015Henry JiCEOBuy500$0.95$475.00View SEC Filing  
8/24/2015Henry JiCEOBuy8,888$12.84$114,121.92View SEC Filing  
8/21/2015Henry JiCEOBuy8,888$13.08$116,255.04View SEC Filing  
11/10/2014Henry JiCEOBuy5,999$4.83$28,975.17View SEC Filing  
11/7/2014Henry JiCEOBuy4,000$4.56$18,240.00View SEC Filing  
11/6/2014Henry JiCEOBuy3,000$4.53$13,590.00View SEC Filing  
12/5/2013Henry JiCEOBuy1,000$8.92$8,920.00View SEC Filing  
12/4/2013Henry JiCEOBuy1,000$8.54$8,540.00View SEC Filing  
11/25/2013Jaisim ShahDirectorBuy1,000$8.65$8,650.00View SEC Filing  
11/22/2013Henry JiCEOBuy1,000$8.47$8,470.00View SEC Filing  
11/22/2013Opko Health, Inc.Major ShareholderSell8,471$8.50$72,003.50View SEC Filing  
11/21/2013George UyInsiderBuy3,000$8.36$25,080.00View SEC Filing  
11/21/2013Opko Health, Inc.Major ShareholderSell4,269$8.53$36,414.57View SEC Filing  
11/20/2013Opko Health, Inc.Major ShareholderSell17,062$8.75$149,292.50View SEC Filing  
11/19/2013George UyInsiderBuy2,031$8.61$17,486.91View SEC Filing  
11/19/2013Henry JiCEOBuy2,000$8.59$17,180.00View SEC Filing  
11/19/2013Jaisim ShahDirectorBuy1,000$9.00$9,000.00View SEC Filing  
11/15/2013Opko Health, Inc.Major ShareholderSell2,710$8.75$23,712.50View SEC Filing  
11/14/2013Opko Health, Inc.Major ShareholderSell1,900$8.75$16,625.00View SEC Filing  
11/13/2013Opko Health, Inc.Major ShareholderSell13,457$8.75$117,748.75View SEC Filing  
11/8/2013Opko Health, Inc.Major ShareholderSell2,000$8.75$17,500.00View SEC Filing  
11/7/2013Opko Health, Inc.Major ShareholderSell120,380$9.03$1,087,031.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sorrento Therapeutics (NASDAQ SRNE)

Source:
DateHeadline
Sorrento Therapeutics, Inc. (SRNE) Given a $6.00 Price Target by Oppenheimer Holdings, Inc. AnalystsSorrento Therapeutics, Inc. (SRNE) Given a $6.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - November 19 at 10:20 PM
ETFs with exposure to Sorrento Therapeutics, Inc. : November 17, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : November 17, 2017
finance.yahoo.com - November 18 at 11:56 AM
Q1 2018 Earnings Forecast for Sorrento Therapeutics, Inc. Issued By Oppenheimer Holdings (SRNE)Q1 2018 Earnings Forecast for Sorrento Therapeutics, Inc. Issued By Oppenheimer Holdings (SRNE)
www.americanbankingnews.com - November 17 at 11:00 PM
Sorrento Therapeutics (SRNE) Subsidiary Files MAA For ZTlido - StreetInsider.comSorrento Therapeutics (SRNE) Subsidiary Files MAA For ZTlido - StreetInsider.com
www.streetinsider.com - November 15 at 11:16 AM
Sorrento Therapeutics (SRNE) Subsidiary Files MAA For ZTlidoSorrento Therapeutics (SRNE) Subsidiary Files MAA For ZTlido
www.streetinsider.com - November 15 at 11:16 AM
Scilex Pharmaceuticals, Sorrento Therapeutics Subsidiary, Files Marketing Authorization Application In The European Union For ZTlido™Scilex Pharmaceuticals, Sorrento Therapeutics' Subsidiary, Files Marketing Authorization Application In The European Union For ZTlido™
finance.yahoo.com - November 15 at 11:16 AM
Sorrento Therapeutics, Inc. (SRNE) Receives Average Rating of "Buy" from AnalystsSorrento Therapeutics, Inc. (SRNE) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 11 at 1:46 AM
Critical Survey: Sorrento Therapeutics (SRNE) & Its CompetitorsCritical Survey: Sorrento Therapeutics (SRNE) & Its Competitors
www.americanbankingnews.com - November 8 at 1:18 AM
Breakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, Marinus Pharma, and NewLink GeneticsBreakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, Marinus Pharma, and NewLink Genetics
www.prnewswire.com - November 7 at 11:02 AM
Sorrento Therapeutics (SRNE) & Its Rivals Critical AnalysisSorrento Therapeutics (SRNE) & Its Rivals Critical Analysis
www.americanbankingnews.com - November 7 at 10:58 AM
ETFs with exposure to Sorrento Therapeutics, Inc. : November 2, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : November 2, 2017
finance.yahoo.com - November 4 at 5:06 PM
Sorrento Therapeutics (SRNE) versus Its Rivals Financial SurveySorrento Therapeutics (SRNE) versus Its Rivals Financial Survey
www.americanbankingnews.com - November 2 at 1:28 AM
Sorrento Therapeutics, Inc. (SRNE) Expected to Post Quarterly Sales of $4.23 MillionSorrento Therapeutics, Inc. (SRNE) Expected to Post Quarterly Sales of $4.23 Million
www.americanbankingnews.com - October 30 at 1:02 AM
Adgero Biopharmaceuticals Appoints John Liatos as Chief Financial OfficerAdgero Biopharmaceuticals Appoints John Liatos as Chief Financial Officer
finance.yahoo.com - October 25 at 11:11 AM
ETFs with exposure to Sorrento Therapeutics, Inc. : October 23, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : October 23, 2017
finance.yahoo.com - October 24 at 10:27 AM
Sorrento Therapeutics, Inc. (SRNE) Given Average Rating of "Buy" by BrokeragesSorrento Therapeutics, Inc. (SRNE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 17 at 2:52 AM
Sorrento Therapeutics, Inc. (SRNE) Sees Significant Decrease in Short InterestSorrento Therapeutics, Inc. (SRNE) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 15 at 2:20 AM
ETFs with exposure to Sorrento Therapeutics, Inc. : October 10, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : October 10, 2017
finance.yahoo.com - October 11 at 8:04 AM
Head-To-Head Survey: Sorrento Therapeutics (SRNE) and Epizyme (EPZM)Head-To-Head Survey: Sorrento Therapeutics (SRNE) and Epizyme (EPZM)
www.americanbankingnews.com - October 11 at 6:28 AM
H.C. Wainwright Sees Over 1000% Upside for Sorrento Therapeutics (SRNE)H.C. Wainwright Sees Over 1000% Upside for Sorrento Therapeutics (SRNE)
finance.yahoo.com - October 6 at 12:46 PM
Sorrento Therapeutics, Inc. (SRNE) Stock Rating Reaffirmed by HC WainwrightSorrento Therapeutics, Inc. (SRNE) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - October 5 at 4:56 PM
Technical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento TherapeuticsTechnical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento Therapeutics
www.bizjournals.com - October 3 at 12:52 PM
Sorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of DirectorsSorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of Directors
www.thestreet.com - October 2 at 9:16 AM
Sorrento Therapeutics, Inc. (SRNE) Given Consensus Rating of "Buy" by BrokeragesSorrento Therapeutics, Inc. (SRNE) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 22 at 2:34 AM
Sorrento Therapeutics, Inc. To Present At Cantor Global Healthcare Conference (09/25/17 - 2:25 PM ET)Sorrento Therapeutics, Inc. To Present At Cantor Global Healthcare Conference (09/25/17 - 2:25 PM ET)
finance.yahoo.com - September 20 at 9:26 AM
Sorrento Therapeutics, Inc. (SRNE) Given Buy Rating at HC WainwrightSorrento Therapeutics, Inc. (SRNE) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - September 18 at 10:16 PM
FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido™; PDUFA Date Set For February 28, 2018FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido™; PDUFA Date Set For February 28, 2018
finance.yahoo.com - September 12 at 10:14 AM
Sorrento Therapeutics, Inc. To Present At 19th Rodman And Renshaw Global Investment Conference (09/11/17 - 17:30 ET)Sorrento Therapeutics, Inc. To Present At 19th Rodman And Renshaw Global Investment Conference (09/11/17 - 17:30 ET)
finance.yahoo.com - September 9 at 8:52 AM
ETFs with exposure to Sorrento Therapeutics, Inc. : September 1, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : September 1, 2017
finance.yahoo.com - September 4 at 6:52 AM
ETFs with exposure to Sorrento Therapeutics, Inc. : September 1, 2017ETFs with exposure to Sorrento Therapeutics, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 9:07 AM
Sorrento Therapeutics (SRNE) Submits ZTlido NDASorrento Therapeutics (SRNE) Submits ZTlido NDA
www.streetinsider.com - August 31 at 10:24 AM
FY2017 Earnings Forecast for Sorrento Therapeutics, Inc. (SRNE) Issued By Oppenheimer HoldingsFY2017 Earnings Forecast for Sorrento Therapeutics, Inc. (SRNE) Issued By Oppenheimer Holdings
www.americanbankingnews.com - August 31 at 9:06 AM
Sorrento Therapeutics, Inc. to Post Q1 2019 Earnings of ($0.16) Per Share, Oppenheimer Holdings Forecasts (SRNE)Sorrento Therapeutics, Inc. to Post Q1 2019 Earnings of ($0.16) Per Share, Oppenheimer Holdings Forecasts (SRNE)
www.americanbankingnews.com - August 30 at 1:28 PM
HC Wainwright Analysts Give Sorrento Therapeutics, Inc. (SRNE) a $20.00 Price TargetHC Wainwright Analysts Give Sorrento Therapeutics, Inc. (SRNE) a $20.00 Price Target
www.americanbankingnews.com - August 30 at 11:16 AM
Sorrento Therapeutics (SRNE) Submits ZTlido NDA - StreetInsider.comSorrento Therapeutics (SRNE) Submits ZTlido NDA - StreetInsider.com
www.streetinsider.com - August 30 at 9:35 AM
Oppenheimer Holdings, Inc. Analysts Give Sorrento Therapeutics, Inc. (SRNE) a $7.00 Price TargetOppenheimer Holdings, Inc. Analysts Give Sorrento Therapeutics, Inc. (SRNE) a $7.00 Price Target
www.americanbankingnews.com - August 29 at 4:46 PM
Sorrento Therapeutics, Inc. Submits NDA For ZTlido™ Next-Generation Lidocaine PatchSorrento Therapeutics, Inc. Submits NDA For ZTlido™ Next-Generation Lidocaine Patch
finance.yahoo.com - August 29 at 8:11 AM
Sorrento Therapeutics, Inc. (SRNE) Given Consensus Rating of "Buy" by AnalystsSorrento Therapeutics, Inc. (SRNE) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 28 at 2:36 AM
Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 25 at 4:30 PM
Sorrento Therapeutics (SRNE): Celularity Deal Could Generate Allogeneic Products - Oppenheimer - StreetInsider.comSorrento Therapeutics (SRNE): Celularity Deal Could Generate Allogeneic Products - Oppenheimer - StreetInsider.com
www.streetinsider.com - August 23 at 11:57 AM
Sorrento Contributes To The Formation Of Celularity, Inc. For Breakthrough Placental Therapeutic Platform In Consortium With Leading Pharmaceutical CompaniesSorrento Contributes To The Formation Of Celularity, Inc. For Breakthrough Placental Therapeutic Platform In Consortium With Leading Pharmaceutical Companies
finance.yahoo.com - August 23 at 11:57 AM
Q3 2017 EPS Estimates for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Increased by AnalystQ3 2017 EPS Estimates for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Increased by Analyst
www.americanbankingnews.com - August 14 at 2:06 AM
-$0.34 EPS Expected for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) This Quarter-$0.34 EPS Expected for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) This Quarter
www.americanbankingnews.com - August 13 at 10:30 AM
Sorrento Therapeutics, Inc. Expected to Post FY2021 Earnings of $0.44 Per Share (NASDAQ:SRNE)Sorrento Therapeutics, Inc. Expected to Post FY2021 Earnings of $0.44 Per Share (NASDAQ:SRNE)
www.americanbankingnews.com - August 11 at 5:22 PM
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Receives New Coverage from Analysts at Oppenheimer Holdings, Inc.Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Receives New Coverage from Analysts at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - August 6 at 8:28 PM
Sorrento Therapeutics, Inc. (SRNE) Now Covered by Analysts at Roth CapitalSorrento Therapeutics, Inc. (SRNE) Now Covered by Analysts at Roth Capital
www.americanbankingnews.com - August 3 at 6:38 PM
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Given Consensus Recommendation of "Buy" by AnalystsSorrento Therapeutics, Inc. (NASDAQ:SRNE) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 3 at 6:34 PM
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Now Covered by UBS AGSorrento Therapeutics, Inc. (NASDAQ:SRNE) Now Covered by UBS AG
www.americanbankingnews.com - August 3 at 5:24 PM
 Analysts Anticipate Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Will Post Quarterly Sales of $4.40 Million Analysts Anticipate Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Will Post Quarterly Sales of $4.40 Million
www.americanbankingnews.com - July 28 at 7:52 PM
$4.40 Million in Sales Expected for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) This Quarter$4.40 Million in Sales Expected for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) This Quarter
www.americanbankingnews.com - July 2 at 11:02 AM

Social Media

Financials

Chart

Sorrento Therapeutics (NASDAQ SRNE) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.